Gällande vårdprogram malignt melanom

Fastställt av Regionala cancercentrum i samverkan 2017-05-16

18. Referenser

1. Australiensiska och Nya Zeeländska (ANZ:s) riktlinjer  [Available from: http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/ClinicalPracticeGuidelines-ManagementofMelanoma.pdf.

2. Melanomföreningen  [Available from: http://melanomforeningen.se/.

3. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. European journal of cancer (Oxford, England : 1990). 2010;46(2):270-83.

4. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. Journal of the American Academy of Dermatology. 2011;65(5):1032-47.

5. Cancer Council Australia  [Available from: http://www.cancer.org.au/health-professionals/clinical-guidelines/skin-cancer.html.

6. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. The British journal of dermatology. 2010;163(2):238-56.

7. Global Cancer Observatory  [Available from: http://gco.iarc.fr/.

8. Projektet NORDCAN  [Available from: http://www-dep.iarc.fr/NORDCAN/SW/frame.asp.

9. Cancerincidens i Sverige 2014. Nya diagnosticerade cancerfall år 2014: Socialstyrelsen; 2015 [Available from: http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/20008/2015-12-26.pdf.

10. Socialstyrelsen. Statistikdatabas för cancer  [Available from: http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer.

11. Socialstyrelsen. Statistikdatabas för dödsorsaker  [Available from: http://www.socialstyrelsen.se/statistik/statistikdatabas/dodsorsaker.

12. Hudmelanom - Årsrapport nationellt kvalitetsregister. Diagnosår 1990-2015: Regionalt cancercentrum i Samverkan; 2016 [Available from: http://www.cancercentrum.se/globalassets/cancerdiagnoser/hud/kvalitetsregister/nationell-kvalitetsregisterrapport-hudmelanom-1990-2015.pdf.

13. Lindholm C, Andersson R, Dufmats M, Hansson J, Ingvar C, Moller T, et al. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer. 2004;101(9):2067-78.

14. Lyth J, Hansson J, Ingvar C, Mansson-Brahme E, Naredi P, Stierner U, et al. Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. The British journal of dermatology. 2013;168(4):779-86.

15. Eriksson H, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, et al. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden. European journal of cancer (Oxford, England : 1990). 2013;49(12):2705-16.

16. Eriksson H, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, et al. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1356-64.

17. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(36):6199-206.

18. Lyth J, Mikiver R, Nielsen K, Isaksson K, Ingvar C. Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register. European journal of cancer (Oxford, England : 1990). 2016;59:171-8.

19. Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. Journal of the American Academy of Dermatology. 2012;67(1):1.e-16; quiz 7-8.

20. Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. Journal of the American Academy of Dermatology. 2012;67(1):19.e1-2; quiz 31-2.

21. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399):502-6.

22. Dutton-Regester K, Hayward NK. Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment cell & melanoma research. 2012;25(2):144-54.

23. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.

24. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. The New England journal of medicine. 2010;363(9):809-19.

25. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011;364(26):2507-16.

26. Davies JR, Chang YM, Bishop DT, Armstrong BK, Bataille V, Bergman W, et al. Development and validation of a melanoma risk score based on pooled data from 16 case-control studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2015;24(5):817-24.

27. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. European journal of cancer (Oxford, England : 1990). 2005;41(1):28-44.

28. Emeny J, Hansson J, Toftgard R, Segerback D. Meeting report of the conference on UV-Radiation-Induced Disease--Roles of UVA and UVB. The Journal of investigative dermatology. 2008;128(8):1875-7.

29. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand 2008 [Available from: http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/ClinicalPracticeGuidelines-ManagementofMelanoma.pdf.

30. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, et al. Clinicopathological features of and risk factors for multiple primary melanomas. Jama. 2005;294(13):1647-54.

31. Hansson J, Bergenmar M, Hofer PA, Lundell G, Mansson-Brahme E, Ringborg U, et al. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(19):2819-24.

32. Helgadottir H, Hoiom V, Jonsson G, Tuominen R, Ingvar C, Borg A, et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. Journal of medical genetics. 2014;51(8):545-52.

33. Helgadottir H, Hoiom V, Tuominen R, Jonsson G, Mansson-Brahme E, Olsson H, et al. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. International journal of cancer. 2015;137(9):2220-6.

34. Socialstyrelsen.  [Available from: http://www.socialstyrelsen.se/nationellariktlinjerforsjukdomsforebyggandemetoder/.

35. WHO Cardiovascular diseases (CVDs), Fact sheet No 317 och WHO Cancer, Fact sheet No 297. 2011.

36.     Socialdepartementet. En nationell cancerstrategi för framtiden, SOU 2009:11. Stockholm: Fritzes offentliga publikationer; 2009.

37. Robles-Espinoza CD, Roberts ND, Chen S, Leacy FP. Germline MC1R status influences somatic mutation burden in melanoma. 2016;7:12064.

38. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. Journal of photochemistry and photobiology B, Biology. 2001;63(1-3):8-18.

39. Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society. 2003;16(3):297-306.

40. Branstrom R, Chang YM, Kasparian N, Affleck P, Tibben A, Aspinwall LG, et al. Melanoma risk factors, perceived threat and intentional tanning: an international online survey. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2010;19(3):216-26.

41. Branstrom R, Kasparian NA, Chang YM, Affleck P, Tibben A, Aspinwall LG, et al. Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(9):2199-210.

42.  Strålsäkerhetsmyndigheten  [Available from: http://www.stralsakerhetsmyndigheten.se/start/Sol-och-solarier/

43. Westerdahl J, Olsson H, Masback A, Ingvar C, Jonsson N, Brandt L, et al. Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. American journal of epidemiology. 1994;140(8):691-9.

44. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(3):257-63.

45. Ghiasvand R, Weiderpass E, Green AC, Lund E, Veierod MB. Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.

46. Elder DE. Thin melanoma. Archives of pathology & laboratory medicine. 2011;135(3):342-6.

47. Bergenmar M, Hansson J, Brandberg Y. Detection of nodular and superficial spreading melanoma with tumour thickness < or = 2.0 mm--an interview study. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2002;11(1):49-55.

48. McPherson M, Elwood M, English DR, Baade PD, Youl PH, Aitken JF. Presentation and detection of invasive melanoma in a high-risk population. Journal of the American Academy of Dermatology. 2006;54(5):783-92.

49. Blum A, Ingvar C, Avramidis M, von Kannen A, Menzies SW, Olsson H, et al. Time to diagnosis of melanoma: same trend in different continents. Journal of cutaneous medicine and surgery. 2007;11(4):137-44.

50. Puig S, Argenziano G, Zalaudek I, Ferrara G, Palou J, Massi D, et al. Melanomas that failed dermoscopic detection: a combined clinicodermoscopic approach for not missing melanoma. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 2007;33(10):1262-73.

51. Menzies A. Dermatoscopy. An Atlas of Surface Microscopy of Pigmented Skin Lesions. . Sidney: McGraw-Hill; 2003. 173 p.

52. Menzies SW, Zalaudek I. Why perform dermoscopy? The evidence for its role in the routine management of pigmented skin lesions. Archives of dermatology. 2006;142(9):1211-2.

53. Bowling J, Argenziano G, Azenha A, Bandic J, Bergman R, Blum A, et al. Dermoscopy key points: recommendations from the international dermoscopy society. Dermatology (Basel, Switzerland). 2007;214(1):3-5.

54. Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Archives of dermatology. 2008;144(4):502-6.

55. Kittler H, Guitera P, Riedl E, Avramidis M, Teban L, Fiebiger M, et al. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. Archives of dermatology. 2006;142(9):1113-9.

56. Haenssle HA, Krueger U, Vente C, Thoms KM, Bertsch HP, Zutt M, et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. The Journal of investigative dermatology. 2006;126(5):980-5.

57. Menzies SW, Gutenev A, Avramidis M, Batrac A, McCarthy WH. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Archives of dermatology. 2001;137(12):1583-9.

58. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. The Lancet Oncology. 2002;3(3):159-65.

59. Clark WH, Jr., From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer research. 1969;29(3):705-27.

60. Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular oncology. 2011;5(2):124-36.

61. Grin CM, Rojas AI, Grant-Kels JM. Does pregnancy alter melanocytic nevi? Journal of cutaneous pathology. 2001;28(8):389-92.

62. Gunduz K, Koltan S, Sahin MT, E EF. Analysis of melanocytic naevi by dermoscopy during pregnancy. Journal of the European Academy of Dermatology and Venereology : JEADV. 2003;17(3):349-51.

63. Katz VL, Farmer RM, Dotters D. Focus on primary care: from nevus to neoplasm: myths of melanoma in pregnancy. Obstetrical & gynecological survey. 2002;57(2):112-9.

64. Andersson TM, Johansson AL, Fredriksson I, Lambe M. Cancer during pregnancy and the postpartum period: A population-based study. Cancer. 2015;121(12):2072-7.

65. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(1):45-51.

66. Dillman RO, Vandermolen LA, Barth NM, Bransford KJ. Malignant melanoma and pregnancy ten questions. The Western journal of medicine. 1996;164(2):156-61.

67. Driscoll MS, Martires K, Bieber AK, Pomeranz MK, Grant-Kels JM, Stein JA. Pregnancy and melanoma. Journal of the American Academy of Dermatology. 2016;75(4):669-78.

68. O'Meara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. Cancer. 2005;103(6):1217-26.

69. Lens MB, Rosdahl I, Ahlbom A, Farahmand BY, Synnerstad I, Boeryd B, et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(21):4369-75.

70. Lens M, Rosdahl I, Newton-Bishop J. Cutaneous melanoma during pregnancy: is the controversy over? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(19):e11-2; author reply e3-4.

71. Reintgen DS, McCarty KS, Jr., Vollmer R, Cox E, Seigler HF. Malignant melanoma and pregnancy. Cancer. 1985;55(6):1340-4.

72. MacKie RM, Bufalino R, Morabito A, Sutherland C, Cascinelli N. Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet (London, England). 1991;337(8742):653-5.

73. Schwartz JL, Mozurkewich EL, Johnson TM. Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. Cancer. 2003;97(9):2130-3.

74. Maleka A, Enblad G, Sjors G, Lindqvist A, Ullenhag GJ. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(11):e192-3.

75. Peccatori FA, Azim HA, Jr., Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24 Suppl 6:vi160-70.

76. Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. The New England journal of medicine. 2015;373(19):1824-34.

77. Karlsson P, Boeryd B, Sander B, Westermark P, Rosdahl I. Increasing incidence of cutaneous malignant melanoma in children and adolescents 12-19 years of age in Sweden 1973-92. Acta dermato-venereologica. 1998;78(4):289-92.

78. Karlsson PM, Fredrikson M. Cutaneous malignant melanoma in children and adolescents in Sweden, 1993-2002: the increasing trend is broken. International journal of cancer. 2007;121(2):323-8.

79. Karlsson M. Sun Exposure, Prevalence and Localization of Common Melanocytic Naevi in Swedish Children. Solna: Institutionen För Medicin, Karolinska Institutet; 2015.

80. Trumble ER, Smith RM, Pearl G, Wall J. Transplacental transmission of metastatic melanoma to the posterior fossa. Case report. Journal of neurosurgery. 2005;103(2 Suppl):191-3.

81. Ceballos PI, Ruiz-Maldonado R, Mihm MC, Jr. Melanoma in children. The New England journal of medicine. 1995;332(10):656-62.

82. Youl P, Aitken J, Hayward N, Hogg D, Liu L, Lassam N, et al. Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia. International journal of cancer. 2002;98(1):92-8.

83. Whiteman DC, Valery P, McWhirter W, Green AC. Risk factors for childhood melanoma in Queensland, Australia. International journal of cancer. 1997;70(1):26-31.

84. Leman JA, Evans A, Mooi W, MacKie RM. Outcomes and pathological review of a cohort of children with melanoma. The British journal of dermatology. 2005;152(6):1321-3.

85. Spitz S. Melanomas of childhood. The American journal of pathology. 1948;24(3):591-609.

86. Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. The American journal of surgical pathology. 2010;34(3):314-26.

87. Lallas A, Kyrgidis A, Ferrara G, Kittler H, Apalla Z, Castagnetti F, et al. Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. The Lancet Oncology. 2014;15(4):e178-83.

88. Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2006;19 Suppl 2:S21-33.

89. Mills O, Messina JL. Pediatric melanoma: a review. Cancer control : journal of the Moffitt Cancer Center. 2009;16(3):225-33.

90. Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(11):1363-8.

91. Daryanani D, Plukker JT, Nap RE, Kuiper H, Hoekstra HJ. Adolescent melanoma: risk factors and long term survival. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2006;32(2):218-23.

92. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(21):4735-41.

93. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. The Journal of investigative dermatology. 1991;97(2):197-202.

94. Moehrle M, Metzger S, Schippert W, Garbe C, Rassner G, Breuninger H. "Functional" surgery in subungual melanoma. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 2003;29(4):366-74.

95. Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 1998;9(4):419-22.

96. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(4):535-41.

97. Clinical practice guidelines for the management of melanoma in Australia and new Zealand. In: MoHA G, editor. 2009.

98. Tadiparthi S, Panchani S, Iqbal A. Biopsy for malignant melanoma--are we following the guidelines? Annals of the Royal College of Surgeons of England. 2008;90(4):322-5.

99. Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, et al. U.K. guidelines for the management of cutaneous melanoma. The British journal of dermatology. 2002;146(1):7-17.

100. Ng PC, Barzilai DA, Ismail SA, Averitte RL, Jr., Gilliam AC. Evaluating invasive cutaneous melanoma: is the initial biopsy representative of the final depth? Journal of the American Academy of Dermatology. 2003;48(3):420-4.

101.Karimipour DJ, Schwartz JL, Wang TS, Bichakjian CK, Orringer JS, King AL, et al. Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. Journal of the American Academy of Dermatology. 2005;52(5):798-802.

102. Somach SC, Taira JW, Pitha JV, Everett MA. Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens. Archives of dermatology. 1996;132(11):1297-302.

103. Farrahi F, Egbert BM, Swetter SM. Histologic similarities between lentigo maligna and dysplastic nevus: importance of clinicopathologic distinction. Journal of cutaneous pathology. 2005;32(6):405-12.

104. Martin RC, 2nd, Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Edwards MJ, et al. Is incisional biopsy of melanoma harmful? American journal of surgery. 2005;190(6):913-7.

105. Piris A, Mihm MC, Jr., Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. Journal of cutaneous pathology. 2011;38(5):394-400.

106. Gershenwald JE SR, Hess KR, et al. Melanoma of the Skin. In: AJCC Cancer Staging ed. Chicago: American Joint Committee on Cancer, ; 2017.

107. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. The New England journal of medicine. 2014;370(7):599-609.

108. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. The New England journal of medicine. 2015;373(20):1926-36.

109. Barnhill R, Piepkorn, M., Busam, K. Pathology of Melanocytic Nevi and Melanoma: Springer-Verlag Berlin and Heidelberg GmbH & Co. K; 2014. 664 p.

110. Elder DE, Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology. 2004;36(5):428-34.

111. Kossard S. Atypical lentiginous junctional naevi of the elderly and melanoma. The Australasian journal of dermatology. 2002;43(2):93-101.

112. Elder DE. Melanoma progression. Pathology. 2016;48(2):147-54.

113. Reddy KK, Farber MJ, Bhawan J, Geronemus RG, Rogers GS. Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma. JAMA dermatology. 2013;149(8):928-34.

114. Riber-Hansen R, Sjoegren P, Hamilton-Dutoit SJ, Steiniche T. Extensive pathological analysis of selected melanoma sentinel lymph nodes: high metastasis detection rates at reduced workload. Annals of surgical oncology. 2008;15(5):1492-501.

115. Luo S, Lobo AZ, Tanabe KK, Muzikansky A, Durazzo T, Sober A, et al. Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes. JAMA surgery. 2015;150(5):465-72.

116. Bradish JR, Richey JD, Post KM, Meehan K, Sen JD, Malek AJ, et al. Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015;28(4):480-6.

117. Egberts F, Bohne AS, Kruger S, Hedderich J, Rompel R, Haag J, et al. Varying Mutational Alterations in Multiple Primary Melanomas. The Journal of molecular diagnostics : JMD. 2016;18(1):75-83.

118. Cochran AM, Buchanan PJ, Bueno RA, Jr., Neumeister MW. Subungual melanoma: a review of current treatment. Plastic and reconstructive surgery. 2014;134(2):259-73.

119. Ethun CG, Delman KA. The importance of surgical margins in melanoma. Journal of surgical oncology. 2016;113(3):339-45.

120. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97(8):1941-6.

121. MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelmarT)  [Available from: https://clinicaltrials.gov/ct2/show/NCT02385214.

122. Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. Journal of the American Academy of Dermatology. 2012;67(1):60-8.

123. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(16):3622-34.

124. Amersi F, Morton DL. The role of sentinel lymph node biopsy in the management of melanoma. Advances in surgery. 2007;41:241-56.

125.Chapman BC, Gleisner A, Kwak JJ, Hosokawa P, Paniccia A, Merkow JS, et al. SPECT/CT Improves Detection of Metastatic Sentinel Lymph Nodes in Patients with Head and Neck Melanoma. Annals of surgical oncology. 2016;23(8):2652-7.

126. Mattsson J, Bergkvist L, Abdiu A, Aili Low JF, Naredi P, Ullberg K, et al. Sentinel node biopsy in malignant melanoma: Swedish experiences 1997-2005. Acta oncologica (Stockholm, Sweden). 2008;47(8):1519-25.

127. Riber-Hansen R, Nyengaard JR, Hamilton-Dutoit SJ, Steiniche T. Stage migration after minor changes in histologic estimation of tumor burden in sentinel lymph nodes: the protocol trap. Cancer. 2009;115(10):2177-87.

128. Gomez-Rivera F, Santillan A, McMurphey AB, Paraskevopoulos G, Roberts DB, Prieto VG, et al. Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: recurrence and survival study. Head & neck. 2008;30(10):1284-94.

129. Erman AB, Collar RM, Griffith KA, Lowe L, Sabel MS, Bichakjian CK, et al. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer. 2012;118(4):1040-7.

130. Kupferman ME, Kubik MW, Bradford CR, Civantos FJ, Devaney KO, Medina JE, et al. The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck. American journal of otolaryngology. 2014;35(2):226-32.

131. Patuzzo R, Maurichi A, Camerini T, Gallino G, Ruggeri R, Baffa G, et al. Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. The Journal of surgical research. 2014;187(2):518-24.

132. Hafstrom A, Romell A, Ingvar C, Wahlberg P, Greiff L. Sentinel lymph node biopsy staging for cutaneous malignant melanoma of the head and neck. Acta oto-laryngologica. 2016;136(3):312-8.

133. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. The New England journal of medicine. 2006;355(13):1307-17.

134. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, 3rd, Daud A, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(4):395-407.

135. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. The Lancet Oncology. 2016;17(6):757-67.

136. Thompson A. Textbook of Melanoma: Martin Dunitz; 2004.

137. Coates AS, Ingvar CI, Petersen-Schaefer K, Shaw HM, Milton GW, O'Brien CJ, et al. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991. Journal of the American College of Surgeons. 1995;180(4):402-9.

138. Hansson J, Ringborg U, Lagerlof B, Afzelius LE, Augustsson I, Blomquist E, et al. Elective lymph node dissection in stage I cutaneous malignant melanoma of the head and neck. A report from the Swedish Melanoma Study Group. Melanoma research. 1994;4(6):407-11.

139. NZGG. Clinical Practice Guidelines for the management of Melanoma in Australia and New Zeeland, N.Z.G Group Editor 2008. The Cancer Council Australia/Australian Cancer Network/ministry of Health, New Zeeland: Wellington. 2008.

140. Nathansohn N, Schachter J, Gutman H. Patterns of recurrence in patients with melanoma after radical lymph node dissection. Archives of surgery (Chicago, Ill : 1960). 2005;140(12):1172-7.

141. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, et al. Melanoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7(3):250-75.

142. Stewart CL, Gleisner A, Kwak J, Chapman B, Pearlman N, Gajdos C, et al. Implications of Sentinel Lymph Node Drainage to Multiple Basins in Head and Neck Melanoma. Annals of surgical oncology. 2017;24(5):1386-91.

143. Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Archives of otolaryngology--head & neck surgery. 2002;128(7):751-8.

144. van der Ploeg AP, van Akkooi AC, Schmitz PI, van Geel AN, de Wilt JH, Eggermont AM, et al. Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Annals of surgical oncology. 2011;18(12):3300-8.

145. Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma: EAGLE-FM. ACTRN12614000721606, Australia and New Zealand Clinical Trials Registry.

146. Heenan PJ, Ghaznawie M. The pathogenesis of local recurrence of melanoma at the primary excision site. British journal of plastic surgery. 1999;52(3):209-13.

147. Gerschenwald. Staging sytems for cutaneos melanomain textbook of Melanoma. Editors martin Dunitz: London. 2004:172.

148. Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(8):2053-7.

149. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 1995;21(4):285-90.

150. Hayes AJ, Clark MA, Harries M, Thomas JM. Management of in-transit metastases from cutaneous malignant melanoma. The British journal of surgery. 2004;91(6):673-82.

151. Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Annals of surgery. 2003;238(5):743-7.

152. Greene G. AJCC cancer staging manual 6th ed. Springer New York. 2002.

153. Kimsey TF, Cohen T, Patel A, Busam KJ, Brady MS. Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Annals of surgical oncology. 2009;16(5):1176-83.

154. Campana LG, Testori A, Curatolo P, Quaglino P, Mocellin S, Framarini M, et al. Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016.

155. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(25):2780-8.

156. Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. The oncologist. 2010;15(4):416-27.

157. Deroose JP, Grunhagen DJ, Eggermont AM, Verhoef C. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. Melanoma research. 2015;25(5):427-31.

158. Olofsson Bagge R, Mattsson J, Hafstrom L. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2014;30(5):295-8.

159. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998;16(9):2906-12.

160. Donnelly. Cutaneous malanoma: A national clinical guideline. 1 st ed 2003. Scottish Intercollegiate Guidelines Network:Edinburgh. 2003.

161. Dossett LA, Ben-Shabat I, Olofsson Bagge R, Zager JS. Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. Annals of surgical oncology. 2016;23(7):2330-5.

162. Theodore JE, Frankel AJ, Thomas JM, Barbour AP, Bayley GJ, Allan CP, et al. Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. ANZ journal of surgery. 2016.

163. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996;14(1):7-17.

164. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000;18(12):2444-58.

165. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(5):1670-7.

166. Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. The Lancet Oncology. 2011;12(2):144-52.

167. Wheatley. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. . June 20 Supplement), 2007: 8526: Journal of Clinical Oncology; 2007.

168. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (London, England). 2008;372(9633):117-26.

169. Stadler R, Luger T, Bieber T, Kohler U, Linse R, Technau K, et al. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta oncologica (Stockholm, Sweden). 2006;45(4):389-99.

170. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European journal of cancer (Oxford, England : 1990). 2012;48(2):218-25.

171. Ascierto PA, Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, et al. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Critical reviews in oncology/hematology. 2013;85(2):149-61.

172. Loquai C, Schmidtmann I, Beutel M, Sunderkotter C, Grabbe S, Schiller M, et al. Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-alpha2b: patients' and doctors' views. European journal of dermatology : EJD. 2011;21(6):976-84.

173. Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, et al. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. European journal of cancer (Oxford, England : 1990). 2012;48(13):2012-9.

174. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. The New England journal of medicine. 2016.

175. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106(7):1431-42.

176. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England journal of medicine. 2011;364(26):2517-26.

177. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 2015;16(4):375-84.

178. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology. 2015;16(8):908-18.

179. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2015;372(26):2521-32.

180. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010;363(8):711-23.

181. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015;373(13):1270-1.

182. Martya M. Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard OperatingProcedures of Electrochemotherapy) study: European Journal of Cancer; 2006.

183. Omholt K, Grafstrom E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(12):3933-42.

184. Kilic E, Bruggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, Luyten GP, et al. The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma research. 2004;14(3):203-5.

185. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet Oncology. 2014;15(3):323-32.

186. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England). 2012;380(9839):358-65.

187. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. The New England journal of medicine. 2012;367(2):107-14.

188. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England journal of medicine. 2012;367(18):1694-703.

189. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England journal of medicine. 2015;372(1):30-9.

190. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 2015;386(9992):444-51.

191. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. The Lancet Oncology. 2016;17(9):1248-60.

192. Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. British medical bulletin. 1995;51(3):609-30.

193. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer investigation. 2003;21(6):821-9.

194. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). European journal of cancer (Oxford, England : 1990). 2011;47(10):1476-83.

195. Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015;26(11):2267-74.

196. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. The oncologist. 2011;16(1):5-24.

197. Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106(2):375-82.

198. Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Seminars in cancer biology. 2003;13(6):409-15.

199. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(10):2346-57.

200. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16(9):2646-55.

201. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(32):5233-9.

202. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(7):1664-73.

203. Bibault JE, Dewas S, Mirabel X, Mortier L, Penel N, Vanseymortier L, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiation oncology (London, England). 2011;6:12.

204. Agrawal S, Kane JM, 3rd, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009;115(24):5836-44.

205. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. The Lancet Oncology. 2012;13(6):589-97.

206. Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. The Lancet Oncology. 2015;16(9):1049-60.

207. Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1986;5(3):183-92.

208. Kirova YM, Chen J, Rabarijaona LI, Piedbois Y, Le Bourgeois JP. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma research. 1999;9(6):611-3.

209. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. International journal of radiation oncology, biology, physics. 1991;20(3):429-32.

210.Forschner A, Zips D, Schraml C, Rocken M, Iordanou E, Leiter U, et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma research. 2014;24(5):512-6.

211. Saco M, Mitchell C. Severe radiation dermatitis associated with concomitant vemurafenib therapy in a patient with metastatic melanoma. Journal of the American Academy of Dermatology. 2014;70(6):e135-6.

212. Wallach JB, Rietschel P, Kalnicki S, Fox JL. BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions. Practical radiation oncology. 2014;4(5):e213-6.

213. Houriet C, Klass ND, Beltraminelli H, Borradori L, Oberholzer PA. Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib. Case reports in dermatology. 2014;6(3):213-7.

214. Conen K, Mosna-Firlejczyk K, Rochlitz C, Wicki A, Itin P, Arnold AW, et al. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology (Basel, Switzerland). 2015;230(1):1-4.

215. Peuvrel L, Ruellan AL, Thillays F, Quereux G, Brocard A, Saint-Jean M, et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. European journal of dermatology : EJD. 2013;23(6):879-81.

216. Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). International journal of radiation oncology, biology, physics. 2016;95(2):632-46.

217. Selek U, Chang EL, Hassenbusch SJ, 3rd, Shiu AS, Lang FF, Allen P, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. International journal of radiation oncology, biology, physics. 2004;59(4):1097-106.

218. Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer. 2012;118(9):2486-93.

219. Ziegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. International journal of radiation oncology, biology, physics. 1986;12(10):1839-42.

220. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. Journal of neurosurgery. 2000;93(1):9-18.

221. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. Jama. 1998;280(17):1485-9.

222. Hunter GK, Suh JH, Reuther AM, Vogelbaum MA, Barnett GH, Angelov L, et al. Treatment of five or more brain metastases with stereotactic radiosurgery. International journal of radiation oncology, biology, physics. 2012;83(5):1394-8.

223. Mohammadi AM, Recinos PF, Barnett GH, Weil RJ, Vogelbaum MA, Chao ST, et al. Role of Gamma Knife surgery in patients with 5 or more brain metastases. Journal of neurosurgery. 2012;117 Suppl:5-12.

224. Frakes JM, Figura NB, Ahmed KA, Juan TH, Patel N, Latifi K, et al. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. Journal of neurosurgery. 2015;123(5):1261-7.

225. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet Oncology. 2014;15(4):387-95.

226.   Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(34):3810-6.

227. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology. 2016;17(7):976-83.

228. Patel BG, Ahmed KA, Johnstone PA, Yu HH, Etame AB. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma research. 2016;26(4):382-6.

229. Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016;122(19):3051-8.

230. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. International journal of radiation oncology, biology, physics. 2015;92(2):368-75.

231. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment cell & melanoma research. 2016;29(6):627-42.

232. Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, et al. Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer immunology research. 2016;4(3):179-82.

233. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer medicine. 2013;2(6):899-906.

234. Ascierto PA, Bastholt L, Hersey P, Cinat G, Eggermont AM, Hauschild A, et al. Side effects and toxicities of targeted therapies in stage IV melanoma. American journal of therapeutics. 2015;22(1):44-53.

235. Sollner W, Zschocke I, Zingg-Schir M, Stein B, Rumpold G, Fritsch P, et al. Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics. 1999;40(3):239-50.

236. Boyle DA. Psychological adjustment to the melanoma experience. Seminars in oncology nursing. 2003;19(1):70-7.

237. Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers D, et al. Impact of melanoma on patients' lives among 562 survivors: a Dutch population-based study. Archives of dermatology. 2011;147(2):177-85.

238. McLoone J, Watts K, Menzies S, Meiser B, Butow P, Kasparian N. When the risks are high: psychological adjustment among melanoma survivors at high risk of developing new primary disease. Qualitative health research. 2012;22(8):1102-13.

239. Oliveria SA, Hay JL, Geller AC, Heneghan MK, McCabe MS, Halpern AC. Melanoma survivorship: research opportunities. Journal of cancer survivorship : research and practice. 2007;1(1):87-97.

240. Patientlag 2014:821. In: Socialdepartementet, editor.

241. Hälso- och sjukvårdslagen (1982:763). In: Socialdepartementet, editor.

242. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA: a cancer journal for clinicians. 2000;50(4):215-36; quiz 37-40.

243. Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004;73(2):153-62.

244.Iwakawa M, Noda S, Yamada S, Yamamoto N, Miyazawa Y, Yamazaki H, et al. Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast cancer (Tokyo, Japan). 2006;13(3):300-7.

245.Sharp L, Johansson H, Hatschek T, Bergenmar M. Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast (Edinburgh, Scotland). 2013;22(5):634-8.

246.Prochazka M, Granath F, Ekbom A, Shields PG, Hall P. Lung cancer risks in women with previous breast cancer. European journal of cancer (Oxford, England : 1990). 2002;38(11):1520-5.

247.Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109(4):650-7.

248.Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(3):392-8.

249.Macdonald G, Kondor N, Yousefi V, Green A, Wong F, Aquino-Parsons C. Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004;73(3):367-71.

250.Tonnesen H, Nielsen PR, Lauritzen JB, Moller AM. Smoking and alcohol intervention before surgery: evidence for best practice. British journal of anaesthesia. 2009;102(3):297-306.

251.Nath B, Li Y, Carroll JE, Szabo G, Tseng JF, Shah SA. Alcohol exposure as a risk factor for adverse outcomes in elective surgery. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2010;14(11):1732-41.

252.Bradley KA, Rubinsky AD, Sun H, Bryson CL, Bishop MJ, Blough DK, et al. Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. Journal of general internal medicine. 2011;26(2):162-9.

253.Peterson C. Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen. 2005:102.

254.Malekzadeh F, et al. Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter 2005:102.

255.Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ, et al. Follow-up schedules after treatment for malignant melanoma. The British journal of surgery. 2008;95(11):1401-7.

256.Nieweg OE, Kroon BB. The conundrum of follow-up: should it be abandoned? Surgical oncology clinics of North America. 2006;15(2):319-30.

257.Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(3):520-9.

258.Jillela. The role for close follow-up of melanoma patients with AJCC stage I-III: a prelimary analysis: Proc Am Soc Clin Oncol; 1995. 14:413 p.

259. Kersey PA, Iscoe NA, Gapski JA, Osoba D, From L, DeBoer G, et al. The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. The British journal of surgery. 1985;72(8):614-7.

260. Ruark. Who detects the primary reccurence in stage I cutaneous melanoma: patient or doctor? melanoma Res. 1993;3 Supplement 1:441993.

261. Rychetnik L, McCaffery K, Morton R, Irwig L. Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psycho-oncology. 2013;22(4):721-36.

262. Murchie P, Delaney EK, Campbell NC, Hannaford PC. GP-led melanoma follow-up: views and feelings of patient recipients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2010;18(2):225-33.